



# Recurrent Platinum Refractory/Resistant Ovarian Efficacy (n=19)



## EFFICACY

<b>ORR, %*</b>	<b>26% (95% CI, 9-51%)</b>
<b>BOR, n (%)</b>	
CR	1 (5)
PR	4 (21)
SD	7 (37)
PD	7 (37)
<b>DCR (CR + PR + SD), %</b>	<b>63% (95% CI, 38-84%)</b>
<b>Median DOR, months</b>	NR (95% CI, 4.2-NR)
<b>Median F/U, months</b>	6.5 (Range, 2.0-24.0)

- Responder Characteristics (n=5)**
- 4 high grade serous (80%), 1 endometrioid/clear cell (20%)
  - 3/5 (60%) with 3L+ prior LOT
  - 1/5 (20%) with prior I-O (pembrolizumab/PI3Ki PD, nivolumab PD)
  - 5/5 (100%) MSS
  - 0/3 (0%) TMB >10 mut/Mb
  - 3/3 (100%) PD-L1 positive (≥1%)
  - 2/5 (40%) responses ongoing



\*Includes unconfirmed responses.  
 ∞ SD for 72 weeks on monotherapy prior to switching to combination.

+Ongoing response.  
 ⚡ Received radiation, no evidence of disease.